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Background: The purpose of this study is to evaluate the impact on the health-related quality of life (HRQoL) of
sunitinib versus interferon-alpha (IFN-a) treatment in patients with metastatic renal cell carcinoma (mRCC).
Patients and methods: In all, 304 mRCC patients (European cohort) were randomized 1 : 1 to receive sunitinib (50
mg/day for 4 weeks, followed by 2 weeks off) or IFN-a (9 million units s.c. injection three times/week). The following
questionnaires were completed (days 1 and 28 per cycle): Functional Assessment of Cancer Therapy-General (FACT-
G), the FACT-Kidney Symptom Index and the EuroQol Group’s EQ-5D self-report questionnaire (EQ-5D). Results
correspond to an ongoing trial with progression-free survival time as primary end point, and patients were still being
followed up. Data were analyzed using repeated measures mixed effects models (MEMs) that allow the inclusion of
initial differences and uncompleted repeated measures, with the assumption of data missing at random. Six-cycle
results were included.
Results: Results consistently showed that patients in sunitinib group experienced statistically significantly milder
kidney-related symptoms, better cancer-specific HRQoL and general health status (in social utility scores) during the
study period as measured by these patient-reported outcome end points. No statistical differences between groups
were found on the FACT-G physical well-being subscale or the EQ-5D VAS values.
Conclusions: Results from MEM showed the sunitinib’s benefit on HRQoL compared with IFN-a.
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introduction
A patient-reported outcome (PRO) is a measurement of any
aspect of a patient’s health status that comes directly from the
patient. The importance of evaluating PROs in clinical trials is
based on the possibility that some treatment effects are known
only to the patient; clinician reports of treatment effectiveness
may not reflect the patient’s perspective; or aspects of the
patient’s perspective may be lost if his/her response is filtered
through a clinician interview. PRO measurements are
particularly important in clinical trials in which two treatments
with similar efficacy may have different safety profiles that have
an impact on patients’ symptoms, functioning, or health-
related quality of life (HRQoL). PROs therefore complement
and extend information provided by clinical end points on the
efficacy and side-effects of treatment [1].
A phase III, randomized study was conducted to compare the
efficacy and safety as well as PROs for sunitinib versus
interferon-alpha (IFN-a) as first-line systemic therapy for
patients with metastatic renal cell carcinoma (mRCC) [2]. The
present study summarizes the PRO (kidney-related symptoms,
cancer-specific HRQoL, and general health status) reported for
the European patients at the moment of the interim analysis of
this study.
mRCC treatment is intended to delay disease progression,
prolong survival, and improve HRQoL. The symptoms,
various sites of metastases, and generally poor prognosis
associated with mRCC may negatively affect HRQoL and
specific aspects such as physical functioning, energy/fatigue
level, mental status, sexual functioning, and perceived well-
being [3]. Treatment side-effects may also affect patient
HRQoL. In considering drugs for metastatic diseases,
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improved PROs even in the absence of impact on survival
(relative to standard care) may be considered in regulatory
approval decisions [4].
The immediate effect of treatment is on symptoms. Moving
further along the continuum, social/psychological and other
non-medical factors such as personality, motivation,
attitude, individual preferences, and family support affect
HRQoL and functional outcomes, so that even patients who
experience symptom reduction may not demonstrate
a commensurate improvement in HRQoL. For these reasons,
we assessed the effect of treatment on more proximal
symptom outcomes separately from the effect on more distal
HRQoL outcomes.
patients and methods
The PRO instruments used in this study were (i) designed to measure either
general cancer-specific or kidney cancer-specific outcomes, (ii) developed
and validated in relevant populations, and (iii) studied and reported in the
peer-reviewed literature [5].
Table 1 presents a summary of the PRO instruments used in this study
[6–9]. The Functional Assessment of Cancer Therapy–Kidney Symptom
Index–Disease-Related Symptoms (FKSI-DRS) scale was prespecified in the
trial’s protocol as the primary PRO end point. We hypothesized that
sunitinib would show a more positive impact than IFN-a on patients’
symptom experience. In addition, we used the FKSI, the parent instrument
of the FKSI-DRS, to measure the impact of treatment on both disease- and
treatment-related symptoms and the Functional Assessment of Cancer
Therapy-General (FACT-G) to measure the impact of treatment on general
cancer-related HRQoL and functioning. Although the EuroQol Group’s
EQ-5D self-report questionnaire (EQ-5D) was also included in this trial
primarily for the estimation of quality-adjusted life years in economic
analysis, those results are also reported here as the EQ-5D is a generic
HRQoL instrument. All instruments were used in their pertinent cultural
adapted version.
The overall objective of PRO assessment in this study was to compare
PROs between the two treatment arms. Specifically, the PRO assessment
was to compare the effects of sunitinib and IFN-a throughout the course of
treatment on patient self-reports of (i) kidney cancer-specific symptoms;
(ii) cancer-specific HRQoL and well-being/functioning in related
fundamental domains; and (iii) societal and patient values (utilities) for
patient-perceived health status.
relationship between PRO measures
Although all PROs included in this study were designed to measure
outcomes of kidney cancer, each of the instruments measures outcomes at
different points along the outcomes continuum. Correlation coefficients
across the PRO end point scores as baseline were calculated to explore the
relationships between the symptoms, cancer-specific HRQoL, functioning
and well-being, and overall HRQoL.
study sample, treatments, and clinical assessments
The target population is composed of patients >18 years old, living in an
European country with mRCC who had not previously been treated with
systemic therapy.
A sample of 304 patients was recruited at random in France, Germany,
Italy, Poland, Spain, and United Kingdom. Patients were 18 years old or
older, presented mRCC, who had not previously been treated with systemic
therapy, and had evidence of measurable disease and an Eastern
Cooperative Oncology Group [10] performance status of zero or one.
Patients were randomized to receive either sunitinib or IFN-a in
repeated 6-week cycles. Sunitinib was administered as an oral capsule at
50 mg daily for 4 weeks followed by 2 weeks of treatment in repeated
6-week cycles of treatment. IFN-a was administered as a s.c. injection in
6-week cycles on three nonconsecutive days per week. Subjects in the
IFN-a group received three million units (MU) per dose during the
first week, 6 MU per dose the second week, and 9 MU per dose thereafter.
Dose modifications were allowed for toxicity management on both
treatments.
Initially, the intention-to-treat sample was used for analysis of PRO end
points, which included all subjects who were randomized, with treatment
assignment designated according to initial randomization, regardless of
whether subjects received study treatment or a drug different from the one
to which they were randomized.
Statistical analyses were carried out after 97 survivors (33% of recruited
patients) had reached the sixth treatment cycle follow-up. At that time, 93
patients had terminated treatment because of the lack of efficacy (31%) and
105 (36%) were still at a previous follow-up stage.
PRO assessments
PROs were measured at the screening visit before randomization,
throughout the treatment period, and at the end of treatment or patient
withdrawal from the study. During the treatment period, subjects were
asked to complete the questionnaires during their visits on days 1 and 28 of
each 42-day treatment cycle. The assessment on cycle 1 day 1 was
administered before the first dose of study medication thus was used as the
baseline measurement.
statistical analysis
Questionnaire compliance was defined as a patient having answered at least
one question at an assessment time point. Compliance rate at each
assessment time point for each questionnaire was calculated as the number
of patients who completed at least one question divided by the total
number of patients available at that assessment time point.
Scoring of the PRO end points (scales) and missing data were handled
according to the questionnaires’ scoring guidelines. If there were missing
items, subscale scores were prorated by first multiplying the sum of the
subscale by the number of items in the subscale and then dividing by the
number of items actually answered. Completion for an instrument was
defined as having >80% item responses for the total FACT-G or having
>50% item responses for FACT-G subscales, FKSI, and FKSI-DRS. PRO
end points with less than the minimum number of items answered were
scored as missing. For EQ-5D, the EQ-5D index [11] will be missing, if
not all five descriptors were responded. For all PRO end points, a higher
score indicated a favourable outcome (less/milder symptoms, better
functioning, or QoL). The scale completion rate for a PRO end point at an
assessment time point was defined as the number of patients with non-
missing scores divided by the number of patients who responded to at least
one question of the end point.
Summary statistics of absolute scores of the PRO end points and their
changes from baseline were calculated at each assessment time point
for the two treatments. The mean (and 95% confidence interval) and
median (and interquartile ranges) of the absolute scores and the changes
from baseline were reported for the FKSI-DRS, FKSI, FACT-G total and
its four subscales [physical well-being (PWB), emotional well-being
(EWB), social well-being (SWB), and functional well-being (FWB)],
EQ-5D index, and EQ-visual analog scale (VAS).
Repeated measures mixed-effects models (MEMs) were used to assess the
between-treatment differences for all the PRO end points. There are several
features that make the MEM attractive and useful for this study. First,
subjects with incomplete data across time have been included in the model;
therefore, statistical power increases and potential biases from complete
case analyses are reduced. Secondly, subjects may not have to be measured
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at the same time point because time is treated as a continuous variable, thus
the follow-up times are not required to be uniform for all subjects. Thirdly,
the fact that individual characteristics may change across time due to the
treatment are accommodated by this model, and time-varying covariates
could be included in the model that allow us to treat QoL in ‘real’ time
rather than a specific time point. Fourthly, MEM can also estimate change
for each subject, whereas traditional approaches may only estimate average
change in a population [12–14].
The following MEM for PRO scores across time is used for this study:
yik=b0+b1BSi+b2timeik+b3Txi+b4

timeik·TxiÞ+t0i+t1itimeik+eik;
where yik is the PRO score for individual i at time k, Txi equals 0 if
individual i is in IFN-a group or 1 if individual i is in sunitinib malate
group, and BSi is the baseline score of the PRO instrument. As a result of
the dummy coding for the treatment effect, b0 and b2 represent the trend
Table 1. Summary of the PRO instruments used in the study
FKSI FKSI-DRS FACT-G EQ-5D
Objective Assesses disease-related and
treatment-related symptoms
in patients with advanced
kidney cancer
Assesses disease-related
symptoms in patients
with advanced
kidney cancer
Assesses health-related
quality of life for people
with cancer. Provides
multidimensional, generic
measure of well-being and
functioning for patients with
cancer of any type
Assesses general health
status with a simple
descriptive profile and
a single index value that
can be used in the clinical
and economic evaluation
of health care and
population surveys
Domains N/A N/A (subscale of FKSI) PWB; SWB; EWB; FWB Mobility, self-care, usual
activity, pain/discomfort,
and anxiety/depression
Number of items 15 9 27 items (34 items in
version 4) with five-point
Likert scale
5 (see above) + 1 visual
analogue scale
thermometer that
provides a rating of
health from 0 (worst
imaginable health state)
to 100 (best imaginable
health state)
Psychometric
properties
High internal consistency:
Cronbach’s a 0.84–0.88; high
intraclass correlation (test–retest
reliability): 0.90; convergent
validity: with FACT-G and
FACT-G subscales; discriminant
validity: ECOG-PSR;
responsiveness to change:
GRCS (gender role conflict
scale); MID: 3–5 points
High internal consistency:
Cronbach’s a 0.78; high
intraclass correlation
(test–retest reliability): 0.85;
strong convergent and
discriminant validity and
responsiveness to change
that are similar to those
of the FKSI; MID: 2–3 points
High internal consistency:
Cronbach’s a 0.75–0.92;
high test-retest correlation
coefficient: 0.82–0.92;
concurrent validity: correlation
with FLIC (r = 0.79) and QLI
(r = 0.74). Construct validity:
correlation with mood state:
(r = 0.57–0.69); activity level
(r = 20.56); social desirability
(r = 0.22). Correlation is 0.86
with the FLIC scale, 0.45–0.60
with profile of mood states and
also correlated with ECOG-PSR
rating; MID: N/A
Test–retest reliability:
0.86–0.90; evidence of
construct and
discriminant validity.
Evidence of concurrent
validity with related
measures: correlations
with health assessment
questionnaire (r = 0.46–0.76)
and SF-36 (r = 0.52–0.64);
MID: N/A
Mode Self-administered
(telephone interview)
Self-administered
(telephone interview)
Self-administered
(telephone interview)
Self-administered, observer,
proxy, and telephone
Time (minutes) <10 min <10 min 5–10 min <5 min
Languages English, Chinese,
Dutch, French, and
15 other languages
English, Chinese, Dutch,
French, and 15
other languages
English, French, Spanish, Koran,
and plus 51 other languages
60 official translations including
English, and languages for
South Africa, Asia, Europe,
Latin America, the Middle
East, and Scandinavia
Time frame Past 7 days Past 7 days Past 1 week Current
PRO, patient-reported outcome; FKSI-DRS, Functional Assessment of Cancer Therapy–Kidney Symptom Index–Disease-Related Symptoms; FACT-G,
Functional Assessment of Cancer Therapy-General; EQ-5D, EQ-5D self-report questionnaire; PWB, physical well-being; SWB, social/family well-being; EWB,
emotional well-being; FWB, functional well-being; ECOG-PSR: Eastern Cooperative Oncology Group-Performance Status Rating; FLIC, Functional Living
Index—Cancer; GRCS, Global Rating of Change Scale; HAQ, health assessment questionnaire; MID, minimal important difference; N/A, not available.
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across time for the IFN-a group, while b3 represents a constant difference
between treatments at the beginning of the post-baseline period and b4
represents a differential linear trend between treatments. Thus, improved
PROs will be demonstrated by an upward trend in each instrument that
is a positive value of b2 for IFN-a group and (b2 + b4) for sunitinib
malate group. Finally, as postulated, the above model allows individuals
to deviate from their group trend pattern in terms of intercept (t0i) and
slope (t1i).
The intercept and slope term for time are random effects with an
assumed unstructured variance–covariance matrix. In addition, we assume
that each observation is measured with error and the error terms are
independent of each other. A sandwich estimator was used to estimate the
variance of the fixed effects terms, including baseline scores, treatment
group, and time-by-treatment interaction. For estimation of variance
parameters in MEM, restricted/residual maximum likelihood is preferable
because the maximum likelihood (ML) estimation treats coefficients as
known (instead, they are estimated from data), underestimates variances,
and makes the estimates biased downward (i.e. they are too small in
absolute value) [13]. Thus, all parameter estimates were obtained using
restricted ML estimation.
The estimated parameters of the repeated measures MEM were used to
compute the predicted values of the PRO instruments for each day in
each cycle. In addition, we calculated the least squares means (LSMs)
over the first nine cycles for each PRO measure. The LSM provides an
estimate of the predicted means that have been corrected for unbalanced
structure of the data. In other words, the LSM provides an estimate of the
marginal means over a balanced population. The LSMs were computed
over the first nine cycles because this provides the maximum duration of
PRO data by the time of the data cutoff date. The repeated measures
MEM assumed that the missing data mechanism is ignorable (i.e. missing
at random).
All the data were analyzed using the SPSS 15.0 (SPSS Inc, Chicago, IL).
Tests of statistical significance used a two-sided alpha 0.05.
results
description of the sample
One hundred forty-seven subjects (48%) were randomized
to sunitinib malate, and 157 (52%) were randomized to
IFN-a. No subjects (0.0%) on sunitinib versus four subjects
(1%) on IFN-a withdrew consent and discontinued the study
before receiving their first dose of study medication. The
maximum number of cycles started as of the cutoff date was
11 on sunitinib versus 10 on IFN-a. At the time of the data
cutoff for the interim analysis, 11 (7.5% intention to treat (ITT)
population) versus seven subjects (4.5% ITT population) on
sunitinib versus IFN-a, respectively, were ongoing on study.
Forty-one (27.9%) versus 91 subjects (58.0%), respectively, had
discontinued treatment, and the primary reasons for
discontinuation were lack of efficacy/disease progression
[29 (19.7% ITT population) versus 67 subjects (42.7%)]
and adverse events [10 (7.8%) versus 17 subjects (10.8%)];
in addition, one (0.7%) versus six (3.8%) subjects had
withdrawn consent (including subjects who discontinued
the study before receiving their first dose of study
medication).
Demographic and baseline characteristics for the two groups
are summarized in Table 2. There were no significant
differences between treatment groups in the baseline
characteristics of the patients.
PRO instruments compliance and completion
During the study period, the compliance rates were >94% for
both groups for all the PRO instruments at baseline. Table 3
shows the questionnaire compliance rates by assessment time
point for the FACT-G/FKSI and EQ-5D. After cycle 6 <10% of
the subjects remain in the study, suggesting that average PRO
scores after this period could be unreliable.
For the FACT-G, 40 (1.9%) interleaved measurements of the
total of 2147 sequential measurements were missing,
corresponding to 47 (15.5%) of the 304 subjects; for the FKSI,
29 (1.4%) interleaved measurements were missing,
corresponding to 25 (8.2.1%) subjects; for the EQ-5D, 58
(2.7%) interleaved measurements were missing, corresponding
to 43 (14.1%) subjects.
Among the compliant subjects, the completion rate for the
FKSI-DRS, FSKI, and FACT-G at each assessment period
ranged between 94.2% and 100% for measurements
corresponding to the first six cycles and between 82.1% and
100% for the remaining measurements; for the EQ-5D, the rate
ranged between 93.8% and 100% for measurements
corresponding to the first six cycles and between 82.1% and
100% for the remaining measurements.
Table 2. Summary of demographic and baseline characteristics
Variable Sunitinib
(n = 147)
IFN-a
(n = 153)
Age (year), mean 6 SD 61.0 6 10.9 60.0 6 9.5
Male, n (%) 94 (63.9) 124 (81.0)
Race, n (%)
White 145 (98.6) 148 (96.7)
Black 1 (0.7) 2 (1.3)
Asian 1 (0.7) 1 (0.7)
Others 0 (0.0) 2 (1.3)
Country, n (%)
France 40 (27.2) 42 (27.5)
Germany 8 (5.4) 7 (4.6)
Italy 8 (5.4) 16 (10.5)
Poland 54 (36.7) 48 (31.4)
Russian Federation 12 (8.2) 17 (11.1)
Spain 15 (10.2) 12 (7.8)
United Kingdom 10 (6.8) 11 (7.2)
Weight (kg), mean 6 SD 76.8 6 15.6 79.0 6 15.6
ECOG performance status, n (%)
0 84 (57.1) 84 (54.9)
1 63 (42.9) 66 (43.1)
2a 0 (0.0) 3 (2.0)
Previous nephrectomy (%) 89 89
Previous radiation
therapy (%)
15 13
No. of sites of
metastases 1/2/‡3 (%)
18/26/57 24/29/49
aAll subjects had ECOG performance status of zero or one at the time
eligibility was determined; three subjects in the IFN-a group had ECOG
performance status of two on the day of starting the study treatment.
IFN-a, interferon-alpha; ECOG, Eastern Cooperative Oncology Group; SD,
standard deviation.
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relationship among PRO instruments
Table 4 displays the correlation coefficients of the PRO end
points at baseline. As expected, we find that the correlations
between the FKSI and the FKSI-DRS, the FKSI/FKSI-DRS, and
the physical domains of the FACT-G (PWB and FWB) are
higher than the correlations between the FKSI/FKSI-DRS and
the nonphysical domains of the FACT-G (EWB and SWB). The
total FKSI score is highly correlated with the total FACT-G as
reflected by the functional, emotional, and symptom items in
the FKSI. The FKSI-DRS is less highly correlated with the
FACT-G as reflected by the symptom focus of the FKSI-DRS.
The EQ-5D and the EQ-VAS are moderately correlated with
each other reflecting the fact that the EQ-5D measures
community preferences and the EQ-VAS measures personal
preferences. Both the EQ-5D and the EQ-VAS are more
strongly correlated with the total FKSI, FKSI-DRS, and FACT-
G scores than with each other.
descriptive statistics of PRO end points
There were small but not statistically significant differences in
the baseline scores in all the nine PRO end points (Table 5). To
adjust for the potential impacts of such differences on the
treatment effects, the baseline scores were included in the
repeated measures MEMs for all PRO end points.
results from the repeated measures MEM
The estimated scores for the two treatment arms and the
between-treatment differences for all the PROs, using the
repeated measures MEMs, are presented in Figures 1–9. Due to
the reduction in the effective sample size and hence in the
derived problems in the estimation process, only data for cycles
from one to six were considered in the MEMs.
Table 6 presents the parameter estimates from the repeated
measures MEMs for all nine PRO end points during the post-
baseline period. Using these parameters, we estimated the
predicted values of each PRO instrument and the differences in
these values between the sunitinib and IFN-a groups (Table 7).
In addition, we computed the LSM value for each PRO and
present the estimated differences in the LSMs between the
sunitinib and IFN-a groups (Tables 7 and 8).
All estimated between-treatment differences over time for all
the PRO end points are presented in Table 6 and Figures 2–9
(Note that the baseline time point is not present in these
figures.). Differences favouring sunitinib over IFN-a are
indicated by values >0. The results show that subjects on
sunitinib reported statistically significantly better outcomes on
symptoms (P < 0.009) and disease-specific HRQoL (as
measured by the total FACT-G overall score, P < 0.003) than
IFN-a at all assessment time points. For the functional well-
being assessment, all time points were significantly different
between treatments (P < 0.038), except for one time point
(at cycle 2, day 28, P = 0.061) which was close to significance.
Table 3. Number and percentage of compliant subjects by questionnaire
and assessment period
FACT-G FKSI EQ-5D
n % n % n %
Baseline 286 94.1 291 95.7 293 96.4
Cycle 1, day 28 274 90.1 276 90.8 273 89.8
Cycle 2, day 1 260 85.5 260 85.5 262 86.2
Cycle 2, day 28 227 74.7 227 74.7 221 72.7
Cycle 3, day 1 203 66.8 204 67.1 204 67.1
Cycle 3, day 28 187 61.5 188 61.8 187 61.5
Cycle 4, day 1 160 52.6 162 53.3 164 53.9
Cycle 4, day 28 120 39.5 121 39.8 118 38.8
Cycle 5, day 1 103 33.9 106 34.9 105 34.5
Cycle 5, day 28 71 23.4 73 24.0 70 23.0
Cycle 6, day 1 58 19.1 58 19.1 60 19.7
Cycle 6, day 28 42 13.8 42 13.8 42 13.8
Cycle 7, day 1 22 7.2 23 7.6 23 7.6
Cycle 7, day 28 17 5.6 17 5.6 17 5.6
Cycle 8, day 1 11 3.6 11 3.6 11 3.6
Cycle 8, day 28 2 0.7 2 0.7 2 0.7
Cycle 9, day 1 1 0.3 1 0.3 1 0.3
FACT-G, Functional Assessment of Cancer Therapy-General; FKSI,
Functional Assessment of Cancer Therapy–Kidney Symptom Index; EQ-
5D, EQ-5D self-report questionnaire.
Table 4. Correlation matrix of PRO measures at baseline for all patients in the study
FKSI-DRS FKSI Total FACT-G FACT-G PWB FACT-G SWB FACT-G EWB FACT-G FWB EQ-5D index EQ-VAS
FKSI-DRS 1.000 (291) 0.927 (290) 0.682 (284) 0.844 (286) 0.094a (288) 0.421 (287) 0.523 (289) 0.655 (285) 0.563 (286)
FKSI 0.927 (290) 1.000 (290) 0.837 (285) 0.852 (287) 0.210 (289) 0.535 (288) 0.735 (290) 0.685 (286) 0.650 (287)
Total FACT-G 0.682 (284) 0.837 (285) 1.000 (286) 0.768 (286) 0.527 (286) 0.675 (285) 0.869 (286) 0.626 (282) 0.612 (282)
FACT-G PWB 0.844 (286) 0.852 (287) 0.768 (286) 1.000 (289) 0.093a (289) 0.446 (285) 0.585 (287) 0.721 (285) 0.591 (285)
FACT-G SWB 0.094a (288) 0.210 (289) 0.527 (286) 0.093a (289) 1.000 (291) 0.076a (287) 0.433 (289) 0.066a (287) 0.184 (287)
FACT-G EWB 0.421 (287) 0.535 (288) 0.675 (285) 0.446 (285) 0.076a (287) 1.000 (289) 0.418 (289) 0.370 (284) 0.288 (285)
FACT-G FWB 0.523 (289) 0.735 (290) 0.869 (286) 0.585 (287) 0.433 (289) 0.418 (289) 1.000 (291) 0.580 (286) 0.619 (287)
EQ-5D index 0.655 (285) 0.685 (286) 0.626 (282) 0.721 (285) 0.066a (287) 0.370 (284) 0.580 (286) 1.000 (729) 0.490 (289)
EQ-VAS 0.563 (286) 0.650 (287) 0.612 (282) 0.591 (285) 0.184 (287) 0.288 (285) 0.619 (287) 0.490 (289) 1.000 (294)
Numbers in parentheses indicate number of observations.
aP value for all coefficients <0.002, except those marked.
PRO, patient-reported outcome; FKSI-DRS, Functional Assessment of Cancer Therapy–Kidney Symptom Index–Disease-Related Symptoms; FACT-G,
Functional Assessment of Cancer Therapy-General; EQ-5D, EQ-5D self-report questionnaire; PWB, physical well-being; SWB, social well-being; EWB,
emotional well-being; FWB, functional well-being.
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A similar pattern was observed for the social well-being scale,
which did not attain significance only at one data point (at
cycle 6, day 1, P = 0.308). PWB, EWB, and general HRQoL (as
measured by the generic EQ-5D) tend to detect significant
differences at the beginning of the cycle (day 1) but not always
at the end of the cycle (day 28). Finally, social utility values (as
measured by the EQ-5D utility function) tend to exhibit less
significant differences between treatments, which disappear
after a number of time points (cycle 4).
FKSI and FKSI-DRS
During the treatment period, FKSI-DRS and FKSI scores
exhibited statistically significant patterns favouring the
sunitinib group over the IFN-a group. Based on the mean
treatment differences at all assessment points, patients in the
sunitinib group experienced milder kidney-related symptoms
or treatment-related symptoms than those in the IFN-a group
during the study period (Table 6).
Additional analyses were also carried out using the MEM for
the nine items in the FKSI-DRS, and the results showed that,
compared with the IFN-a group, patients on sunitinib
demonstrated significantly milder symptoms (higher LSM
scores) of bone pain, fatigue, and fevers (Table 8).
These differences were statistically and clinically
meaningful. Compared with the pre-established minimally
important differences (MID), which are two to three points
for FKSI-DRS and three to five points for the FKSI, the
treatment differences were considered clinically meaningful
after cycle 2 day 1 for the FKSI-DRS and FKSI. The average
standardized effect size (SES) was 0.39 for FKSI-DRS (ranging
from 0.07 at cycle 1 day 28 to 0.97 at cycle 7 day 1) and 0.28
for FKSI (ranging from 20.02 at cycle 4 day 28 to 0.85 at cycle
7 day 1), which indicates that the treatment effect on kidney-
related symptoms and treatment-related symptoms was mild
to moderate over the study period based on Cohen’s effect size
criteria [15].
FACT-G
Based on the mean treatment difference for the FACT-G
scores, patients in the sunitinib group experienced statistically
Table 5. Summary of baseline mean scores (SD) in the PRO end points by treatment
Treatment FKSI-DRS FKSI FACT-G FACT-PWB FACT-SWB FACT-EWB FACT-FWB EQ-5D Index EQ-VAS
Sunitinib malate 28.35 (5.82) 43.53 (8.71) 75.96 (14.47) 21.48 (5.78) 21.56 (4.49) 15.76 (4.86) 17.26 (5.52) 0.72 (0.24) 68.57 (18.39)
IFN-a 29.17 (4.81) 44.41 (8.00) 75.59 (15.03) 21.85 (5.25) 21.19 (4.55) 16.04 (4.61) 16.57 (5.69) 0.74 (0.25) 65.95 (19.32)
Difference
(sunitinib 2 IFN-a)
20.82 20.88 0.37 20.37 0.36 20.29 0.68 20.02 2.63
P value for
difference
0.19 0.37 0.83 0.57 0.49 0.61 0.30 0.41 0.23
SD, standard deviation; PRO, patient-reported outcome; FKSI-DRS, Functional Assessment of Cancer Therapy–Kidney Symptom Index–Disease-Related
Symptoms; FACT-G, Functional Assessment of Cancer Therapy-General; EQ-5D, EQ-5D self-report questionnaire; PWB, physical well-being; SWB, social
well-being; EWB, emotional well-being; FWB, functional well-being; IFN-a, interferon-alpha.
Figure 1. Model-estimated Functional Assessment of Cancer Therapy–
Kidney Symptom Index–Disease-Related Symptoms scores by treatment.
Figure 2. Model estimated Functional Assessment of Cancer Therapy–
Kidney Symptom Index scores by treatment.
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better cancer-specific HRQoL compared with patients in the
IFN-a group at each time point (Table 6). Patients in the
sunitinib group experienced better outcomes based on the
social well-being, the emotional well-being, and the functional
well-being.
These differences were statistically and clinically meaningful.
The FACT-G exceeded the pre-established clinically meaningful
difference of five points at all assessment points (see Table 6)
after the first cycle. However, the FWB subscale was the only
subscale that exceeded its MID of two points (after cycle 3, day
1). The treatment effect on cancer-specific HRQoL was mild to
moderate (SES = 0.34, ranging from 0.11 at cycle 3 day 28 to
0.98 at cycle 7 day 28).
EQ-5D
Based on the LSM of EQ-5D index, patients in the sunitinib
group reported better general health status than patients in
the IFN-a group. Cycle-specific differences were statistically
significant at the first day of the cycle, until cycle 5, day 1. The
mean treatment differences for the EQ-VAS were statistically
significant at most time points, except some of the 28th day
data points. Differences between treatment groups decreased
over time and exhibited a roughly similar pattern (Figure 10).
Although these overall differences were statistically significant,
the SES was 20.13 for the EQ-5D index and 0.22 for the EQ-
VAS, indicating that the treatment effect on general health
status was very small. Surprisingly, the pattern of EQ-5D
Figure 3. Model estimated Functional Assessment of Cancer Therapy-
General total scores by treatment.
Figure 4. Model estimated Functional Assessment of Cancer Therapy-
General physical well-being scores by treatment.
Figure 5. Model estimated Functional Assessment of Cancer Therapy-
General social/family well-being scores by treatment.
Figure 6. Model estimated Functional Assessment of Cancer Therapy-
General emotional well-being scores by treatment.
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utility and EQ-VAS LSM predicted scores was very different,
with a faster increasing utility in the INF group. This lack of
consistency between EQ scores advises to interpret results
with care.
discussion
During the past decade, as attention to QoL concerns for cancer
patients has grown, the need for validated PRO instruments has
also increased [16]. Here, we report the results of a phase III,
randomized study of sunitinib versus INF-a as first-line therapy
for patients with mRCC using PRO end points. In contrast,
previous studies that examined the HRQoL among mRCC
patients were either case series [17] or evaluations of other
therapeutic options such as surgery [18] or restricted within
immunotherapy [19–21].
For this study, PRO instruments appropriate for measuring
the relevant concepts were used. The primary PRO end point,
the FKSI-DRS, measured kidney cancer-related symptoms, the
most proximal domain expected to change. The secondary PRO
end points measured treatment and disease-related symptoms
(FKSI) and physical, social, emotional, and functional well-
being (as measured by the subscales of and the FACT-G total
score), more distal but very important outcomes in metastatic
cancer patients. General HRQoL was measured using the EQ-
5D. Each of these PRO instruments is validated in diverse yet
relevant populations and (except for the EQ-5D) have included
patient input into virtually all phases of their development,
including item selection, scale generation (grouping into
domains), and validation.
At each post-baseline assessment time point of the phase III
trial, patients receiving sunitinib reported better scores on the
primary PRO end point (the FKSI-DRS) compared with the
IFN-a group, indicating that those patients who received
sunitinib experienced milder symptoms than those who received
IFN-a. Differences between the sunitinib and IFN-a groups were
statistically significant at each time point and, after the first cycle,
the difference exceeded the minimum clinically important
difference of two points. Based on effect size criteria suggested by
Cohen [15], treatment effect on the kidney-related symptoms
was almost moderate over the study period (SES = 0.38). This
study also examined how patients responded to individual items
within the FKSI-DRS. Results indicate that patients in the
sunitinib group experienced statistically significantly milder
symptoms of bone pain, fatigue, and fever symptoms. These
results are concordant with those reported by Cella et al. [22] on
a worldwide study with a longer follow-up from which our data
are the European subset. Nevertheless, the slope estimate for the
Figure 7. Model estimated Functional Assessment of Cancer Therapy-
General functional well-being scores by treatment.
Figure 8. Model estimated EQ-5D self-report questionnaire utility scores
by treatment.
Figure 9. Model estimated EQ-5D VAS scores by treatment.
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overall model in the European sample is slightly less positive and
the treatment difference is slightly larger.
The secondary PRO end points (the FKSI, the FACT-G total
score and its four subscales, the EQ-5D index, and the EQ-
VAS) also exhibited a similar pattern favouring the sunitinib
group over the IFN-a group. Both the FKSI and the FACT-G
total score exhibited clinically meaningful differences at all
assessment points after the first cycle. Among the FACT-G
subscales, only functional well-being exceeded its minimal
clinically important difference after cycle 3. The treatment
effects on overall cancer-specific HRQoL were mild to
moderate, and such effects were found on the PWB, SWB,
EWB, and FWB subscales, bit mostly at the first day of theT
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Table 7. Comparison of LSMs of PRO end
points over the first six cycles
PRO end points Sunitinib Interferon Difference P value
FKSI-DRS 28.81 26.38 2.43 <0.0001
FKSI 43.14 39.32 3.82 <0.0001
FACT-G total score 75.71 69.27 6.44 <0.0001
FACT-G physical
well-being subscale
20.20 18.82 1.38 0.158
FACT-G social/family
well-being subscale
21.71 20.12 1.59 <0.0001
FACT-G emotional
well-being subscale
16.73 15.67 1.06 0.019
FACT-G functional
well-being subscale
16.81 14.87 1.94 0.019
EQ-5D index (utility score) 0.723 0.674 0.049 0.022
EQ-VAS (health state
hermometer score)
68.10 63.45 4.65 0.100
LSMs were estimated using the repeated measures mixed effects model
controlling for the time, treatment-by-time interaction and baseline score.
A higher score means better outcome (better quality of life or less
symptoms).
LSM, least squares mean; PRO, Patient reported outcome; FKSI-DRS,
Functional Assessment of Cancer Therapy–Kidney Symptom Index–
Disease-Related Symptoms; FACT-G, Functional Assessment of Cancer
Therapy-General; EQ-5D, EQ-5D self-report questionnaire.
Table 8. Item analysis of FKSI-DRS over the cycles (over the first six
cycles)
Items Least squares means
Sunitinib IFN-a P value
I have a lack of energy 2.48 2.19 0.431
I have pain 2.93 2.83 0.809
I am losing weight 3.37 3.18 0.111
I have bone pain 3.15 2.93 0.043
I feel fatigued 2.47 2.19 0.010
I have been short of breath 3.21 2.86 0.058
I have been coughing 3.26 3.12 0.292
I am bothered by fevers 3.82 3.25 <0.0001
I have had blood in my urine 3.94 3.92 0.181
FKSI-DRS, Functional Assessment of Cancer Therapy–Kidney Symptom
Index–Disease-Related Symptoms; IFN-a, interferon-alpha.
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cycle. Similar results for other metastatic cancer treatments
have also been reported in other studies [23–25]. Patients in the
sunitinib group also exhibited favourable effects as measured by
the EQ-5D index and the EQ-VAS compared with patients in
the IFN-a group. These results are also similar to those
previously reported [22], although the larger sample size in the
referred study favours significance. The general pattern for all
PRO measures is similar, including the positive slope and
negative interaction for the EQ-5D measure. LSMs are slightly
lower than those reported previously, but it should be noted
that a shorter follow-up was studied here.
Although there are some missing data over time, the overall
response rate was >95% across the assessment time points.
There were no significant differences in baseline patient
characteristics or PRO end points. The use of the MEM
reduced the potential for bias resulting from missing data by
utilizing all available assessments.
Findings from this longitudinal study provide rich PRO data
derived from a variety of reliable and validated PROs that were
obtained during a phase III, randomized treatment
multinational study. We found that for a number of PRO
measures that were assessed in this study, the differences
favouring the subjects in the sunitinib group exceeded the
minimal clinically important differences. These results are
consistent with the hypothesis that sunitinib offers patients
with mRCC an effective treatment option that results in milder
symptoms, better cancer-related HRQoL, and general health
status than IFN-a.
conclusions
Results from this multinational phase III, randomized study
indicate that, compared with subjects treated with IFN-a,
subjects treated with sunitinib reported less/milder kidney-
cancer related symptoms as measured by the FKSI and FKSI-
DRS and better cancer-related and general HRQoL as measured
by the FACT-G and EQ-5D.
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